Overview
- Gilead and Tempus announced Thursday a multi‑year expansion that gives Gilead enterprise‑wide access to Tempus’ AI Lens platform.
- The agreement extends use of de‑identified, multimodal patient data across many cancer types and adds dedicated analytics from Tempus experts.
- Gilead had already tapped Tempus data for trial design, indication selection, biomarker strategy, health outcomes work, and real‑world evidence, and the new deal formalizes and widens that scope.
- Financial terms were not disclosed, and Tempus highlighted 2025 gains including 111.5% diagnostics revenue growth, $100.4 million in Q4 Data & Applications revenue, and more than $1.1 billion in remaining contract value.
- Tempus says it is building large AI foundation models on its datasets with plans to expand into radiology, cardiology, and neuropsychology, which could set up similar data partnerships beyond oncology.